Narcotics alone

PreclinicalSmall molecule

BBeth Israel Deaconess Medical Center

Narcotics alone is one of 22 small molecule programs targeting Bone Fracture. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone FractureActive, not recruiting

Bone FracturePreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Bone Fracture

#DrugCompanyPhaseTrials

Fareston

Kyowa Kirin Co., Ltd.

Epidiolex

Voltaren

Zometa

Bayer Aspirin

Advil

1 7

Tylenol

KKenvue Brands

Approved

1 8

Ultram

WWim Janssens

Approved

1 9

Esmeron

FFresenius Kabi USA, LLC

Approved

—10

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Fracture1 trial

Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture

Withdrawn·—·N/A·NCT00240396

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Narcotics alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Narcotics alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Narcotics alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beth Israel Deaconess Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBeth Israel Deaconess Medical Center

Narcotics alone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Fracture1 trial

References

Drug Info

Quick Facts

Related News